<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278419</url>
  </required_header>
  <id_info>
    <org_study_id>CR104970</org_study_id>
    <secondary_id>TMC435HPC2014</secondary_id>
    <nct_id>NCT02278419</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection</brief_title>
  <official_title>A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of simeprevir in combination with
      sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of
      participants with sustained virologic response at 12 weeks after end of treatment (SVR12) in
      the overall population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a partly randomized, open-label (identity of study drug will be known to volunteer
      and study staff), multicenter (when more than one hospital or medical school team work on a
      medical research study) study. The study will consist of a screening period of up to 4 weeks,
      an open-label treatment period of 8 weeks or 12 weeks, and a post-treatment follow-up period
      until 24 weeks after end of treatment (EOT). Participants without cirrhosis will be assigned
      to Group A wherein half of the participants will receive 8 week treatment in Group A1 and
      remaining participants will receive 12 week treatment in Group A2. Participants with
      cirrhosis, will be assigned to Group B to receive simeprevir in combination with sofosbuvir
      for 12 weeks. The duration of participation for each participant, including the screening
      period, will be approximately 36 or 40 weeks for 8 or 12 week treatment, respectively.
      Efficacy will be primarily assessed by percentage of participants with SVR12. Participants'
      safety will be evaluated throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at Week 12 After End of Treatment (SVR12)</measure>
    <time_frame>12 weeks after end of treatment (EOT) (EOT; Week 8 for Group A1, Week 12 for Group A2 and Group B)</time_frame>
    <description>SVR12 is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than (&lt;) lower limit of quantification (LLOQ; 15 international unit per milliliter [IU/mL]), detectable or undetectable at 12 weeks after EOT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at Week 4 After End of Treatment (SVR4)</measure>
    <time_frame>4 weeks after EOT (EOT; Week 8 for Group A1, Week 12 for Group A2 and Group B)</time_frame>
    <description>SVR4 is defined as HCV RNA &lt;LLOQ;15 IU/mL, at 4 weeks after EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response at Week 24 After End of Treatment (SVR24)</measure>
    <time_frame>24 weeks after EOT (EOT; Week 8 for Group A1, Week 12 for Group A2 and Group B)</time_frame>
    <description>SVR24 is defined as HCV RNA &lt;LLOQ;15 IU/mL, at 24 weeks after EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With on-treatment Failure</measure>
    <time_frame>EOT (EOT; Week 8 for Group A1, Week 12 for Group A2 and Group B)</time_frame>
    <description>Participants will be considered on-treatment failures if they have (confirmed) detectable HCV RNA, that is &lt;LLOQ;15 IU/mL, detectable or greater than or equal to (&gt;=) LLOQ at EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Relapse</measure>
    <time_frame>EOT (Week 8 for Group A1, Week 12 for Group A2 and Group B), Weeks 4, 12 and 24 after end of treatment</time_frame>
    <description>Participants will be considered to have viral relapse if they do not achieve SVR at Week 4, 12 and 24 after EOT and meet the following conditions 1) HCV RNA &lt;LLOQ;15 IU/mL, undetectable at EOT, 2) HCV RNA &gt;=LLOQ;15 IU/mL during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Response</measure>
    <time_frame>Week 1, 2, 4, 8 and EOT for all groups, Week 12 for Group A2 and Group B</time_frame>
    <description>On-treatment virologic response is defined as the change from baseline in log10 hepatitis C virus ribonucleic acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Breakthrough</measure>
    <time_frame>Week 1 up to Week 8 in Group A1, Week 1 up to Week 12 in Group A2 and Group B</time_frame>
    <description>Viral breakthrough is defined as confirmed &gt;1.0 log10 increase in HCV RNA from nadir or confirmed HCV RNA &gt;100 IU/mL in participants who had previously achieved HCV RNA &lt;LLOQ; 15 IU/mL.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.</description>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.</description>
    <arm_group_label>Group A1</arm_group_label>
    <arm_group_label>Group A2</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have hepatitis C virus (HCV) genotype 4 infection (confirmed at
             screening)

          -  Participant must have HCV ribonucleic acid (RNA) greater than (&gt;) 10,000 international
             unit per milliliter (IU/mL) at screening

          -  In participants with cirrhosis, a documented hepatic imaging procedure (ultrasound,
             computed tomography [CT] scan, or magnetic resonance imaging [MRI]) within 6 months
             before baseline (Day 1) to exclude hepatocellular carcinoma is required

          -  A woman of childbearing potential must have a negative serum (beta human chorionic
             gonadotropin at screening and a negative urine pregnancy test on Day 1 before first
             dose of study drug

          -  Females of childbearing potential or males with a female partner of childbearing
             potential must agree to use 2 highly effective contraceptive methods (one of which is
             a barrier method; eg, condom or diaphragm) from Day 1 (baseline) and continue until 30
             days after the end of treatment (EOT) (or longer if dictated by local regulations), or
             not be heterosexually active, or be a vasectomized male subject or a female subject
             with a vasectomized partner, or be a female (subject or partner of male subject) of
             non-childbearing potential (ie, postmenopausal for at least 2 years or surgically
             sterile)

        Exclusion Criteria:

          -  Participant has evidence of clinical hepatic decompensation (history or current
             evidence of ascites, bleeding varices, or hepatic encephalopathy)

          -  Participant has any liver disease of non-HCV etiology. This includes, but is not
             limited to, acute hepatitis A, drug- or alcohol-related liver disease, autoimmune
             hepatitis, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency,
             non-alcoholic steatohepatitis, primary biliary cirrhosis, or any other non-HCV liver
             disease considered clinically significant by the investigator

          -  Participant is infected/co-infected with non-genotype 4 HCV

          -  Participant has any other active clinically significant disease or clinically
             significant findings during screening of medical history, physical examination,
             laboratory testing or electrocardiogram (ECG) recordings that, in the investigator's
             opinion, would compromise the participant's safety or could interfere with the
             participant participating in and completing the study

          -  Participant has history of malignancy within 5 years of the screening visit
             (exceptions: skin carcinomas, carcinoma in situ of the cervix, or malignancy that in
             the opinion of the investigator is considered cured with minimal risk of recurrence)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Menoufiya</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_7051&amp;studyid=7813&amp;filename=CR104970_CSR.pdf</url>
    <description>A Phase2a,Partly Randomized,Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12 Week Treatment Regimen of Simeprevir in CombinationWith Sofosbuvir in Treatment-Na√Øve and Experienced Subjects With Chronic Genotype 4 HepatitisC Infection</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>Simeprevir</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

